Brett R. Hagen, Senior Vice President, Finance and Chief Accounting Officer of InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.), filed an initial statement of beneficial ownership on November 12, 2026, with a triggering event date of November 6, 2026.

Key Highlights

  • Reporting person: Brett R. Hagen, identified as Senior Vice President, Finance and Chief Accounting Officer of the issuer.
  • Triggering event: A merger effective November 6, 2026, in which Indigo Merger Sub Corp. merged with and into Pre-Merger Mentari Therapeutics, Inc., making it a wholly owned subsidiary of the issuer.
  • Derivative security disclosed: A stock option (right to buy) covering 62,273 shares of common stock at an exercise price of $10.37, expiring September 24, 2036, held directly.
  • Option origin: According to the filing, the option was received in the merger in exchange for options of Pre-Merger Mentari held by Hagen prior to the merger.
  • Vesting schedule: The option vests as to 25% on August 3, 2027, then in equal monthly installments through August 3, 2030, subject to continued service.
  • No non-derivative securities reported: Table I lists no directly or indirectly held non-derivative securities.

Hagen's Initial Ownership Disclosure Following the Mentari Merger

The filing was submitted on behalf of Brett R. Hagen, who holds the title of Senior Vice President, Finance and Chief Accounting Officer at InMed Pharmaceuticals Inc., now operating under the name Mentari Therapeutics, Inc. and trading on NASDAQ:MTRI. The form covers the period beginning November 6, 2026, the date of the event requiring the statement.

According to the filing, the November 6, 2026 merger involved two steps: first, Indigo Merger Sub Corp., a wholly owned subsidiary of the issuer, merged with and into Mentari Therapeutics, Inc. (a Delaware corporation referred to as Pre-Merger Mentari), with Pre-Merger Mentari surviving as a wholly owned subsidiary of the issuer. Immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary, with the surviving entity renamed Mentari Therapeutics Operating Company LLC.

In Table II, the filing discloses one derivative security: a stock option to purchase 62,273 shares of the issuer's common stock at $10.37 per share, expiring September 24, 2036, held directly. The filing states this option was received by Hagen in the merger as a replacement for options he held in Pre-Merger Mentari. The option is scheduled to vest 25% on August 3, 2027, with the remainder vesting in equal monthly installments through August 3, 2030, contingent on continued service. The form was signed by Jerad G. Seurer as attorney-in-fact for Brett Hagen on November 12, 2026.

What Was Disclosed

Brett R. Hagen submitted an initial beneficial ownership statement disclosing one stock option to purchase 62,273 shares of InMed Pharmaceuticals Inc. (Mentari Therapeutics, Inc.) common stock at $10.37, received in connection with a November 6, 2026 corporate merger.